BMRN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioMarin Pharmaceutical Inc (BMRN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential through its acquisition of Amicus and a promising product pipeline, the recent financial performance, declining net income, and lack of immediate positive trading signals suggest waiting for more favorable conditions or a clearer growth trajectory.
The technical indicators show mixed signals. The MACD is positive and expanding, suggesting bullish momentum, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the RSI is neutral at 70.972, and the stock is trading near its pivot level of 58.344 with resistance at 60.712. The stock also has a 70% chance of a slight decline (-0.18%) in the next day and a modest gain (0.97%) in the next week.
Analysts maintain an overall positive outlook with multiple 'Buy' and 'Overweight' ratings and price targets ranging from $80 to $
The acquisition of Amicus is expected to enhance BioMarin's long-term growth and align with its rare disease focus.
The company's gross margin increased to 81.33%, indicating strong operational efficiency.
Recent financial performance shows a significant decline in net income (-128.98% YoY) and EPS (-129.09% YoY).
The stock price has declined in the pre-market (-5.22%) and regular market (-0.61%), with no immediate positive trading signals.
Hedge funds and insiders remain neutral, showing no significant trading activity.
In Q3 2025, BioMarin's revenue increased by 4.08% YoY to $776.13M, but net income dropped significantly to -$30.74M (-128.98% YoY), and EPS fell to -$0.16 (-129.09% YoY). Gross margin improved to 81.33%, up 9.82% YoY, indicating operational efficiency despite declining profitability.
Analysts are generally positive on BMRN, with recent upgrades and price targets ranging from $80 to $100. The acquisition of Amicus is seen as a strategic move that could drive long-term growth, but some analysts note that the payoff is expected in the 2030s, making it a long-term play rather than an immediate opportunity.
